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BACKGROUND:The current standard of care for pancreatic cancer is weekly gemcitabine administered for 3 of 4 weeks with a 1-week
break between treatment cycles. Maximum tolerated dose (MTD)-driven regimens as such are often associated with toxicities.
Recent studies demonstrated that frequent dosing of chemotherapeutic drugs at relatively lower doses in metronomic regimens also
confers anti-tumour activity but with fewer side effects.
METHODS: Herein, we evaluated the anti-tumour efficacy of metronomic vs MTD gemcitabine, and investigated their effects on the
tumour microenvironment in two human pancreatic cancer xenografts established from two different patients.
RESULTS: Metronomic and MTD gemcitabine significantly reduced tumour volume in both xenografts. However, K
trans values were
higher in metronomic gemcitabine-treated tumours than in their MTD-treated counterparts, suggesting better tissue perfusion in the
former. These data were further supported by tumour-mapping studies showing prominent decreases in hypoxia after metronomic
gemcitabine treatment. Metronomic gemcitabine also significantly increased apoptosis in cancer-associated fibroblasts and induced
greater reductions in the tumour levels of multiple pro-angiogenic factors, including EGF, IL-1a, IL-8, ICAM-1, and VCAM-1.
CONCLUSION: Metronomic dosing of gemcitabine is active in pancreatic cancer and is accompanied by pronounced changes in the
tumour microenvironment.
British Journal of Cancer (2010) 103, 52–60. doi:10.1038/sj.bjc.6605727 www.bjcancer.com
Published online 8 June 2010
& 2010 Cancer Research UK
Keywords: tumour microenvironment; pancreatic cancer; metronomic chemotherapy; gemcitabine; anti-angiogenesis
                                                           
Pancreatic ductal adenocarcinoma remains a therapeutic challenge
in oncology. The 5-year survival rate for unresectable disease is
o5% and the median survival is 4–6 months. Current standard
treatment consists of weekly gemcitabine administered at
1000mgm
 2 for 3 weeks, followed by a week of rest before the
next cycle begins. Myelosuppression is the dose-limiting toxicity.
This pulsatile maximum tolerated dose (MTD)-driven gemcitabine
regimen significantly improves clinical benefit response but only
provides modest survival benefits (Burris et al, 1997). Previous
studies indicated that the efficacy and toxicity of gemcitabine are
strongly schedule dependent (Hertel et al, 1990; Braakhuis et al,
1991, 1995; Boven et al, 1993; Veerman et al, 1996). In various
murine and human tumour models, 120mgkg
 1 of gemcitabine
administered every 3 days was shown to induce greater tumour
growth inhibition than 2.5–3.5mgkg
 1 of gemcitabine injected
daily or 240mgkg
 1 of the drug given weekly (Braakhuis et al,
1991, 1995). Furthermore, daily administration of gemcitabine at
1mgkg
 1 was reported to be more toxic than once-weekly
administration at 40mgkg
 1 in one study (Hertel et al, 1990),
but was demonstrated to be non-toxic in another (Laquente et al,
2008). Although these observations illustrated the importance of
dose scheduling in maximising the anti-tumour efficacy and
minimising the toxicity of gemcitabine, the physiological changes
induced by different gemcitabine treatment schedules in the whole
pancreatic tumour in situ have not been investigated. Under-
standing the effect of schedule-dependent drug dosing on tumour
physiology will likely lead to the development of more efficacious
gemcitabine monotherapy or combination chemotherapy with
molecularly targeted agents for pancreatic cancer.
The therapeutic concept of administering cytotoxic agents
continuously at lower doses relative to MTDs without drug-free
breaks over extended periods, known as ‘metronomic chemother-
apy’, is increasingly being recognised as a viable cancer treatment
option. In comparison with MTD regimens, metronomic dosing
protocols demonstrated reduced toxicity but similar or even
increased efficacy in pre-clinical studies (Browder et al, 2000;
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sBertolini et al, 2003). More importantly, several Phase II trials
have now shown that metronomic chemotherapy regimens using
oral cyclophosphamide, methotrexate, etoposide, or capecitabine,
in the absence or presence of agents with anti-angiogenic
properties (e.g., thalidomide, celecoxib, bevacizumab), are active
and minimally toxic in advanced breast cancer (Colleoni et al,
2006; Dellapasqua et al, 2008), recurrent ovarian cancer (Garcia
et al, 2008), hormone refractory prostate cancer (Lord et al, 2007),
and non-Hodgkin’s lymphoma (Buckstein et al, 2006) among other
cancers (Kieran et al, 2005; Young et al, 2006). The mechanistic
basis of metronomic chemotherapy is believed to be primarily
anti-angiogenic, either by direct killing of endothelial cells in the
tumour vasculature (Browder et al, 2000; Klement et al, 2000),
destruction of bone marrow-derived endothelial progenitors
(Bertolini et al, 2003; Shaked et al, 2005), and/or stimulation of
the release of endogenous anti-angiogenic factors such as
thrombospondin-1 from perivascular stromal cells (Hamano
et al, 2004). Moreover, immunostimulation has also been
shown to mediate the anti-tumour effects of metronomic
cyclophosphamide (Hermans et al, 2003; Ghiringhelli et al,
2004; Loeffler et al, 2005). As the majority of pancreatic cancer
patients are elderly and often have poor performance status,
metronomic gemcitabine regimens could be advantageous
compared with conventional MTD-driven weekly gemcitabine,
provided that it is better tolerated and equally or more efficacious.
In this study, we sought to determine whether gemcitabine
administered at lower doses in a metronomic regimen has anti-
tumour activity in pancreatic ductal adenocarcinoma. The first
objective was to evaluate the anti-tumour efficacy of low-dose
metronomic gemcitabine vs MTD-driven weekly gemcitabine, and
the second was to examine their effects on the tumour micro-
environment in primary pancreatic cancer xenografts grown
orthotopically in the pancreas of SCID mice.
MATERIALS AND METHODS
Establishment of orthotopic primary pancreatic cancer
xenografts
Fresh pancreatic ductal adenocarcinoma tissues were obtained,
with institutional ethics review board approval, from patients
undergoing Whipple resection for pancreatic cancer at Vancouver
General Hospital between 2006 and 2008. Resected, non-diagnostic
specimens were washed twice in antibiotic-containing RPMI 1640.
Necrotic tissues were removed, and viable tumour tissues were cut
into small pieces of B2 2 2mm in size and implanted
subcutaneously into male C.B-17 SCID mice (Taconic, German-
town, NY, USA). When the subcutaneous tumours reached 600–
800mm
3, they were excised and cut into small pieces of
B2 2 2mm in size for surgical implantation into the pancreas
of groups of SCID mice as previously described (Ng et al, 2001).
Two primary pancreatic ductal adenocarcinoma xenograft lines
(PaCa8 and PaCa13) established from resected tumour tissues of
two different patients were used in this study. All animal studies
were conducted in accordance with the guidelines of the Canadian
Council for Animal Care.
Treatment regimens
Gemcitabine hydrochloride (Gemzar; Eli Lilly Canada Inc.,
Toronto, ON, Canada) was purchased from the British Columbia
Cancer Agency pharmacy and dissolved in 0.9% saline (Hospira
Healthcare Corp., Montreal, QC, Canada). When the orthotopic
xenografts reached a palpable size of B200–400mm
3, tumour-
bearing mice were randomised into three groups (n¼5 each) and
treated with vehicle control (0.9% saline, i.p.), one cycle of MTD
gemcitabine (240mgkg
 1 on days 1, 8, and 15, i.p., followed by
a 1-week break), or metronomic gemcitabine (30mgkg
 1 on days
1, 4, 7, 10, 13, 16, 19, 22, 25, and 28, i.p.) for 4 weeks. The dose and
schedule used in the MTD gemcitabine regimen were chosen to
emulate clinical treatment protocols. When administered on a
weekly basis, 240mgkg
 1 (B724mgm
 2 for a 20-g mouse) was
previously reported to be the MTD of gemcitabine in mice
(Veerman et al, 1996). Animal weight was monitored twice a week
during the course of treatment.
Dynamic contrast-enhanced magnetic resonance imaging
All studies were conducted using a 7.0T magnetic resonance
scanner (Bruker, Ettlingen, Germany), with a quadrature birdcage
coil for transmission and a 1.7 1.4cm rectangular surface coil for
reception. At the end of the treatment cycle (day 29), the three
groups of tumour-bearing mice were anaesthetised with isoflurane
(Baxter Corporation, Mississauga, ON, Canada) and administered
an i.v. bolus injection of the magnetic resonance contrast agent
gadolinium (Gd)-DTPA (Omniscan; Nycomed, Oslo, Norway) at
0.3mmolkg
 1. Serial images were acquired to monitor changes in
the concentration of the contrast agent in each pixel during the
initial uptake and subsequent washout in the tumour. Magnetic
resonance imaging scans followed the technique previously
described by Lyng et al (1998). Briefly, a proton-density-weighted
spin-echo MSME scan (TE/TR¼11.9/6000ms) was first acquired
to serve as a baseline for conversion of pixel intensity to absolute
concentration values of the contrast agent. Gd-DTPA was injected
using a tail-vein catheter over B15s. Starting at the time of
injection, a series of 41 consecutive T1-weighted scans were
acquired, with each scan lasting 64s (spin-echo MSME, TR/
TE¼11.9/500ms). In-plane spatial resolution was 312mm with
10–14 slices at a thickness of 1mm or 1.5mm, depending on the
size of the tumour. The Gd-DTPA concentration–time curve for
each pixel was fitted to a two-compartment Kety model (Kety,
1960; Tofts et al, 1999) that describes the pharmacokinetics of the
contrast agent using two parameters: K
trans, volume transfer
constant between vascular space and extravascular extracellular
space; and ve, fractional volume of extravascular extracellular
space. K
trans, which is often a mixed measure of blood flow and
vascular permeability (Leach et al, 2003), was determined using in-
house software and expressed as median values of K
trans in viable
tumour tissues.
Immunofluorescence staining and determination of
tumour hypoxia, cell proliferation, and microvessel density
At the end of the treatment cycle (day 29), the three groups
of tumour-bearing mice were injected with hypoxia marker EF5 (Dr
Cameron Koch, University of Pennsylvania, PA, USA) at 30mgkg
 1
i.v. and with proliferation marker BrdU (Sigma, St Louis, MO, USA)
at 1500mgkg
 1 i.p. at 3h and 2h before euthanasia, respectively.
The orthotopic tumours were excised immediately after euthanasia.
Perpendicular tumour diameters were measured with a caliper, and
tumour volumes were calculated using the formula p/6 a b
2,
where a is the longest dimension of the tumour and b is the width.
Tumours were then snap frozen in OCT (Sakura Finetek, Torrance,
CA, USA) in liquid nitrogen. Cryosections of 10 mm were cut from
each tumour and fixed in 50% (v/v) acetone/methanol for 10min at
room temperature. Endothelial cells were stained with a mono-
clonal rat anti-mouse CD31/PECAM-1 antibody (1:100; BD
PharMingen, San Diego, CA, USA), followed by an Alexa 647-
conjugated goat anti-rat secondary antibody (1:200; Molecular
Probes, Eugene, OR, USA). Reduced EF5 adducts in viable hypoxic
cells were stained on the same section using a Cy3-conjugated
monoclonal antibody to ELK3-51 (1:200) (Lord et al, 1993).
Staining for incorporated BrdU was performed as previously
reported (Kyle et al, 2003). Sections were counterstained with
haematoxylin, dehydrated, and mounted. At each stage of staining,
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swhole tumour sections were imaged ( 10 objective) using a
robotic fluorescence microscope (Zeiss Imager Z1, Oberkochen,
Germany), a cooled monochrome CCD camera (Retiga 4000R,
QImaging, Surrey, BC, Canada), a motorised slide loader and x-y
stage (Ludl Electronic Products, Hawthorne, NY, USA), and
customised NIH ImageJ software (http://rsb.info.nih.gov/ij/) run-
ning on a G5 Macintosh computer (Apple, Cupertino, CA, USA). All
parameters stained on the same section were imaged separately,
and subsequently overlaid and aligned with the removal of imaging
artefacts. Tumour hypoxia and cell proliferation were visualised by
EF5þ and BrdUþ staining, respectively. False colour images were
generated using Adobe Photoshop CS3. Using NIH software
applications and user-supplied algorithms, images were cropped
to tumour tissue boundaries with necrosis removed; fluorescent
images were inverted and a threshold was applied to the CD31
image. Neighbouring CD31þ pixels were grouped as CD31þ
objects (i.e., vessels). All image pixels were sorted to determine
their distance from the nearest vessels and the average distance
between vessels, which reflects microvessel density, was reported.
A short average distance between vessels indicates high microvessel
density. The extent of tumour hypoxia or cell proliferation was
reflected by the percentage of EF5þ or BrdUþ pixels, respectively,
which was calculated as the number of EF5þ or BrdUþ pixels
divided by the total number of tumour tissue pixels, and multiplied
by 100%.
Assessment of stromal cell apoptosis in primary xenografts
Cryosections of 10mm were cut, air dried, and fixed in 50% (v/v)
acetone/methanol for 10min at room temperature. Sections were
stained with H&E for histological examination. To detect apoptosis
in cancer-associated fibroblasts, sections were double stained with
a FITC-conjugated monoclonal anti-aSMA antibody (1:200;
Sigma) and an anti-cleaved-caspase 3 antibody (1:200; Cell
Signaling Technology, Danvers, MA, USA), followed by an Alexa
546-conjugated secondary antibody (1:200; Molecular Probes).
To determine apoptosis in endothelial cells, sections were
incubated with anti-CD31/PECAM-1 antibody (1:100), followed
by a FITC-conjugated secondary antibody (1:200; Jackson
ImmunoResearch Laboratories, West Grove, PA, USA), and with
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Figure 1 (A) Representative anatomical magnetic resonance scans of PaCa13 tumours after treatment with vehicle control (0.9% saline), maximum
tolerated dose gemcitabine (MTD gem; 240mgkg
 1 on days 1, 8, and 15), or metronomic gemcitabine (30mgkg
 1, q3d) for 4 weeks. (B) Effects of different
treatments on PaCa8 and PaCa13 tumour growth. Columns, mean of 4–5 tumours; bars, s.e. *Po0.05, significantly different from that of vehicle control.
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santi-cleaved-caspase 3 antibody, followed by the Alexa 546-
conjugated secondary antibody (1:200). Images of whole tumour
sections were captured ( 20 objective) using a Leica fluorescence
microscopic imaging system (Leica Microsystems Inc, Richmond
Hill, ON, Canada) equipped with both cooled 350FX monochrome
and 300FX colour cameras for fluorescence and bright field
imaging, respectively, an automated scanning stage (DM6000B),
and Surveyor software (Objective Imaging, Kansasville, WI, USA).
After removal of artefacts, composite tumour images for aSMA,
CD31, and cleaved-caspase 3 staining were overlaid, aligned,
thresholded, and analysed using in-house software programs
developed in MATLAB (The Mathworks, Natick, MA, USA). The
percentage of apoptotic cancer-associated fibroblasts (CAFs) or
endothelial cells was reported as the number of aSMAþcleaved-
caspase 3þ or CD31þcleaved-caspase 3þ pixels divided by the
total number of aSMAþ or CD31þ pixels, respectively, and
multiplied by 100%.
Evaluation of tumour levels of growth factors
and cytokines
Harvested tumours from all treatment groups were homogenised in
lysis buffer (50mM HEPES, 10% glycerol, 1% Triton X-100, 150mM
NaCl, 1mM EDTA, 1.5mM MgCl2, 100mM NaF, 10mM Na4P2O7,
100mgml
 1 PMSF, 5mgml
 1 leupeptin, and 5mgml
 1 aprotinin)
using a Polytron PT10-35 homogeniser (Kinematica AG, Lucerne,
Switzerland) and stored at  801C. Total protein concentration in
each tumour lysate was determined using a Micro BCA proteins
assay kit (Pierce, Rockford, IL, USA). The protein levels of 89 human
antigens that include numerous growth factors and cytokines were
quantified in the tumour lysates using HumanMAP Antigen version
1.6 (Rules Based Medicine, Austin, TX, USA).
Statistics
All results were presented as mean±s.e. Comparisons were made
with one-way analysis of variance, followed by the Newman–Keuls
test or the Dunnett test, with Po0.05 as the criterion for statistical
significance.
RESULTS
Anti-tumour activity of metronomic gemcitabine
Representative anatomical magnetic resonance scans of PaCa13
tumours after treatment are shown in Figure 1A. The effects of
treatments on tumour volume in the two primary tumour
xenograft lines are summarised in Figure 1B. Metronomic and
MTD gemcitabine significantly decreased the volume of PaCa8
tumours by 99 and 97%, respectively, and that of PaCa13 tumours
by 91 and 84%, respectively, compared with vehicle control. There
was a trend towards greater tumour volume reductions in the
metronomic gemcitabine-treated group compared with the MTD
gemcitabine-treated group. Neither of the treatments caused any
significant weight loss in tumour-bearing mice relative to the
vehicle control, indicating a lack of toxicity (data not shown).
Morphological changes induced by metronomic
gemcitabine in primary pancreatic cancer xenografts
H&E staining of vehicle control-treated PaCa8 xenografts showed
that they are moderately differentiated ductal adenocarcinomas
(Figure 2), whereas PaCa13 xenografts are poorly differentiated
ductal adenocarcinoma (data not shown). PaCa8 tumours were
debulked and seemed to have undergone mucinous differentiation,
with few viable cancer cells remaining after metronomic gemci-
tabine treatment. Mucinous differentiation was also evident,
although to a much lesser extent, with more viable cancer cells
remaining in MTD gemcitabine-treated PaCa8 tumours (Figure 2).
Similar morphological changes, but of lesser extent, were noted in
PaCa13 tumours after metronomic and MTD gemcitabine treat-
ment, with the former inducing more pronounced effects than
the latter (data not shown). Overall, metronomic gemcitabine
exerted greater histological effect than MTD gemcitabine in the
two xenografts.
Effects of metronomic gemcitabine on K
trans in primary
xenografts
Representative K
trans maps of PaCa13 tumours after injection of the
contrast agent Gd-DTPA are shown in Figure 3A. Contrast
enhancement was observed predominantly in the tumour periphery
in the vehicle control and MTD gemcitabine groups. Interestingly,
treatment with metronomic gemcitabine resulted in a uniformly
strong contrast enhancement throughout the entire tumour. K
trans
values were subsequently derived from the maps. In PaCa8 tumours,
the average values for median viable K
trans were significantly higher
in the metronomic and MTD gemcitabine groups (by 2.8- and 2.3-
fold, respectively) compared with the vehicle control group
(Figure 3B). In PaCa13 tumours, metronomic and MTD gemcitabine
also significantly increased K
trans values by 6.8- and 4.1-fold,
respectively, relative to the vehicle control. Moreover, average values
for median viable K
trans were significantly higher in metronomic
gemcitabine-treated PaCa13 tumours compared with their MTD-
treated counterparts (Figure 3B).
MTD gem
Metronomic gem
Vehicle control
Figure 2 Representative composite haematoxylin and eosin (H&E)
images (scale bar: 500mm) of PaCa8 tumours after treatment with vehicle
control (0.9% saline), maximum tolerated dose gemcitabine (MTD gem;
240mgkg
 1 on days 1, 8, and 15), or metronomic gemcitabine
(30mgkg
 1, q3d) for 4 weeks. Squares, magnified images (scale bar:
83mm) of the corresponding areas in the tumour sections.
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sTumour hypoxia, cell proliferation, and microvessel
density after metronomic gemcitabine treatment
Figure 4 shows representative composite images of PaCa13 tumour
sections from different treatment groups. Large areas of EF5þ
staining (red), indicative of hypoxia, were evident in vehicle control-
treated tumours. After MTD gemcitabine treatment, hypoxia
remained prominent in the tumours despite their reduc-
tion in size. In sharp contrast, metronomic gemcitabine-treated
tumours had little or no EF5þ staining. Quantitatively, metronomic
gemcitabine decreased the percentage of EF5þ pixels by 2.2-fold in
PaCa13 tumours compared with the vehicle control; MTD gemci-
tabine had the opposite effect, significantly increasing the percentage
of EF5þ pixels by 2.2-fold (Figure 5A). In PaCa8 tumours,
metronomic and MTD gemcitabine significantly and similarly
reduced hypoxia (Figure 5A). Levels of tumour cell proliferation,
as determined from BrdUþ staining, were similar in all treated
PaCa13 tumours compared with the vehicle control. Similar
observations were also evident in PaCa8 tumours (data not shown).
Microvessel density was reported as the average distance
between CD31þ objects (blue staining in Figure 4) on whole
tumour sections. Short and long average distances between vessels
indicate high and low microvessel density, respectively. In PaCa13
tumours, only metronomic gemcitabine significantly decreased the
average distance between blood vessels and therefore increased
microvessel density (Figure 5A). In PaCa8 tumours, the average
distance between vessels was not significantly altered by metro-
nomic or MTD gemcitabine (Figure 5A).
Effects of metronomic gemcitabine on endothelial cell and
CAF apoptosis
None of the treatments significantly increased endothelial cell
apoptosis in the two primary xenografts, as the percentages
of CD31 and cleaved-caspase 3 double-positive pixels in the
treated tumours were similar to those in vehicle control tumours
(Figure 5B). In PaCa8 tumours, metronomic and MTD gemcitabine
significantly increased CAF apoptosis by 34-fold and 29-fold,
respectively, as reflected by the increased percentages of aSMA and
cleaved-caspase 3 double-positive pixels (Figure 5B). In PaCa13
tumours, there was a trend towards increased CAF apoptosis after
either gemcitabine regimen, but such increases did not reach
statistical significance (Figure 5B).
Tumour levels of growth factors and cytokines in response
to metronomic gemcitabine
Metronomic gemcitabine induced significant changes in the
levels of 37 and 14 out of 89 proteins in the PaCa8 and PaCa13
tumours, respectively, compared with vehicle control (Supplemen-
tary Table S1). The proteins, the levels of which were significantly
reduced following metronomic gemcitabine therapy, were more
numerous in PaCa8 tumours than in PaCa13 tumours (29 vs 13,
respectively). Many of the downregulated proteins are pro-
angiogenic growth factors and cytokines. In general, the decreases
in the levels of these proteins caused by metronomic gemcitabine
were more pronounced than those induced by MTD gemcitabine
(e.g., 21-fold vs 6-fold for CD40 ligand, 12-fold vs 4.1-fold for
EGF, 34-fold vs 20-fold for GM-CSF, 57-fold vs 15-fold for ICAM-1,
397-fold vs 75-fold for IL-1a, and 189-fold vs 18-fold for IL-8,
respectively, in PaCa8 tumours; 8.9-fold vs 1.9-fold for VCAM-1,
2.4-fold vs 1.7-fold for von Willebrand factor, respectively,
in PaCa13 tumours).
DISCUSSION
This study demonstrated that metronomic dosing of gemcitabine
is active against pancreatic ductal adenocarcinoma. It is note-
worthy that, although both metronomic and MTD gemcitabine
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Figure 3 (A) Representative K
trans maps of PaCa13 tumours after treatment with vehicle control (0.9% saline), maximum tolerated dose gemcitabine
(MTD Gem; 240mgkg
 1 on days 1, 8, and 15), or metronomic gemcitabine (30mgkg
 1, q3d) for 4 weeks. (B) Effects of different treatments on median
values of K
trans in viable tumour tissues in PaCa8 and PaCa13 tumours. Each symbol represents an evaluable tumour from a mouse in the corresponding
group. —, mean; bars, s.e. *Po0.05, significantly different from that of vehicle control.
#Po0.05, significantly different from that of MTD gemcitabine.
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sinduced significant tumour volume reductions in PaCa8 and
PaCa13 primary xenografts, the total dose of gemcitabine
administered over 4 weeks in the metronomic group was less
than half of that given in the MTD group (300 vs 720mgkg
 1,
respectively). Metronomic gemcitabine did not induce significant
weight loss in tumour-bearing mice, indicating a lack of toxicity.
These findings suggest that the use of metronomic gemcitabine in
the clinic would be advantageous because such a regimen is more
effective and better tolerated in terms of total drug dose than MTD
weekly gemcitabine.
We then examined what might have contributed to the anti-
tumour effects of metronomic gemcitabine. H&E staining of
tumour sections revealed more prominent morphological changes
that were characterised by more extensive mucinous differentia-
tion, lower overall cell density, and fewer cancer cells in
metronomic gemcitabine-treated tumours compared with their
MTD-treated counterparts. These observations point to a direct
and more pronounced effect of the metronomic regimen on
pancreatic cancer cells. Indeed, it has been suggested that
metronomic chemotherapy might directly affect tumour cells by
inducing their differentiation (Kerbel and Kamen, 2004). Further-
more, tumour cell re-population, which often occurs during
drug-free breaks between cycles of MTD chemotherapy, may also
be prevented using metronomic regimens (Kerbel and Kamen,
2004).
At the functional level, our dynamic contrast-enhanced mag-
netic resonance imaging data demonstrated that metronomic
gemcitabine treatment improves global tumour perfusion. The
strong homogeneous contrast enhancement and the significant
increases in K
trans values observed in metronomic gemcitabine-
treated PaCa8 and PaCa13 tumours in situ were indicative of better
tissue perfusion throughout the tumour. On the other hand,
contrast enhancement was confined to the tumour periphery, and
K
trans values were increased to a lesser extent in MTD gemcitabine-
treated tumours. Improved tissue perfusion after metronomic
gemcitabine treatment was also consistent with the substantial
decreases in hypoxia observed in these tumours. This is
reminiscent of the effects after vessel ‘normalisation’ as reported
by Jain (2001). It is noteworthy that better tissue perfusion did not
result in increased tumour cell proliferation, as BrdU staining in
metronomic gemcitabine-treated tumours was not significantly
different from that in vehicle control- or MTD gemcitabine-treated
tumours. Improved vascular function is likely to promote the
delivery of subsequent doses of gemcitabine itself to the tumour;
thus, the previously reported poor tumour penetration of
gemcitabine, even when administered at MTD (Huxham et al,
2004), might be alleviated with metronomic dosing regimens. As
significant hypoxia has been detected in clinical pancreatic cancer
(Koong et al, 2000), and hypoxia contributes to radioresistance
and chemoresistance, metronomic gemcitabine-induced decreases
in hypoxia could potentially enhance the efficacy of subsequently
administered radiotherapy or MTD-based chemotherapy. The
increases in K
trans values observed in metronomic gemcitabine-
treated PaCa8 and PaCa13 tumours might seem to contradict the
reductions in K
trans values that have often been reported after
treatment with ‘dedicated’ anti-angiogenic agents (Morgan et al,
2003; Batchelor et al, 2007), and more recently with metronomic
capecitabine plus celecoxib (Steinbild et al, 2007). However, the
post-treatment decreases in K
trans values in these studies were not
always accompanied by tumour volume reductions. It is possible
that tumour volume reductions induced by metronomic gemcita-
bine in PaCa8 and PaCa13 tumours might lead to more substantial
decreases in interstitial fluid pressure, thereby markedly improv-
ing the patency of tumour blood vessels and, in turn, tumour blood
flow. As K
trans is a mixed measure of tumour blood flow and
vascular permeability (Strecker et al, 2003; Yankeelov et al, 2006),
an overall increase in K
trans might be detected if the increase in
tumour blood flow is greater than the decrease in vascular
permeability. It is also important to highlight the fact that,
although metronomic and MTD regimens of gemcitabine induced
similar tumour volume reductions in our studies, the two
treatments resulted in different patterns of perfusion.
Given that metronomic chemotherapy has been previously
associated with anti-angiogenesis (Browder et al, 2000; Klement
et al, 2000; Bertolini et al, 2003; Hamano et al, 2004; Shaked et al,
2005), the effects of metronomic vs MTD gemcitabine on
pancreatic tumour vasculature were investigated. PaCa13, but
not PaCa8, tumours showed significant increases in microvessel
density after metronomic gemcitabine treatment. MTD gemcita-
bine had no effect on microvessel density in both xenograft lines.
Neither metronomic nor MTD gemcitabine significantly increased
endothelial cell apoptosis in any of the xenografts. However, it
should be emphasised that microvessel density and possibly
endothelial cell apoptosis are time-dependent measures during
anti-angiogenesis-based therapies (Hlatky et al, 2002). Any
significant endothelial cell dropout might have occurred shortly
after the first or second dose of drug, similar to that previously
reported after cyclophosphamide treatment (Browder et al, 2000),
and therefore might not have been captured at the end of the
4-week treatment period in our study. The anti-angiogenic and
anti-tumour efficacy of metronomic gemcitabine in our primary
xenograft studies could be further attributed to its ability to induce
marked decreases, more so than MTD gemcitabine, in a multitude
Vehicle control
MTD gem
Vehicle control
Metronomic gem
Figure 4 Representative composite images (scale bar: 500mm) of
PaCa13 tumours showing EF5 (red), CD31 (blue), and nuclear (grey)
staining after treatment with vehicle control (0.9% saline), maximum
tolerated dose gemcitabine (MTD gem; 240mgkg
 1 on days 1, 8, and 15),
or metronomic gemcitabine (30mgkg
 1, q3d) for 4 weeks. Squares,
magnified images (scale bar: 83mm) of the corresponding areas in the
tumour sections.
Metronomic gemcitabine and tumour microenvironment
KKY Cham et al
57
British Journal of Cancer (2010) 103(1), 52–60 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sof pro-angiogenic growth factors and cytokines including EGF,
IL-1a, IL-8, MCP-1, ICAM-1, VCAM-1, and others (Supplementary
Table S1). Anti-cancer treatment regimens that cause broad-
spectrum disruption of the tumour growth factor/cytokine net-
work to a greater degree are likely to be more efficacious than
those that only affect a small number of these molecules to a lesser
extent. It is conceivable that the more prominent decreases in
pro-angiogenic growth factors and cytokines after metronomic
gemcitabine therapy ultimately improved tumour vascular func-
tion and tissue perfusion, and led to a corresponding reduction in
tumour hypoxia.
Furthermore, metronomic gemcitabine significantly increased
apoptosis of CAFs in PaCa8 tumours, suggesting that other stromal
components could also be targets of metronomic chemotherapy
regimens. In pancreatic ductal adenocarcinoma, this could be
therapeutically significant, because one of the hallmarks of the
malignancy is the presence of a strong desmoplastic reaction that
is associated with extensive fibroblast proliferation and modified
extracellular matrix deposition. A myriad of pro-angiogenic
molecules, such as VEGF and EGF among others, are known to
be upregulated in CAFs (Bhowmick et al, 2004). Increasing
apoptosis in this cell population would thus deplete the supply
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Figure 5 (A) Effects of treatment with vehicle control (0.9% saline), maximum tolerated dose gemcitabine (MTD gem; 240mgkg
 1 on days 1, 8,
and 15), or metronomic gemcitabine (30mgkg
 1, q3d) for 4 weeks on hypoxia and average distance between vessels in PaCa8 and PaCa13 tumours.
Columns, mean of 3–5 tumours; bars, s.e. *Po0.05, significantly different from that of vehicle control.
#Po0.05, significantly different from that of MTD
gemcitabine. (B) Effects of the three treatments on apoptosis of endothelial cells (CD31 and c-casp3 double-positive pixels) and cancer-associated
fibroblasts (a-SMA and c-casp3 double-positive pixels) in PaCa8 and PaCa13 tumours. Columns, mean of 2–5 tumours; bars, s.e. c-casp3, cleaved-caspase 3.
*Po0.05, significantly different from that of vehicle control.
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sof these molecules and, in turn, restrict angiogenesis and inhibit
tumour growth more effectively. The lack of significant increases
in CAF apoptosis in metronomic gemcitabine-treated PaCa13
tumours might be explained by the differential sensitivity of
individual patient’s CAFs to such treatment. It should be
emphasised that PaCa8 and PaCa13 are primary xenografts
established from surgically resected human pancreatic tumour
tissues. Given the inherent heterogeneity of individual patient’s
tumours and their differential responses to treatments in the
clinical situation, it is not surprising that metronomic and
MTD gemcitabine resulted in different profiles of change of
pro-angiogenic growth factors and cytokines, and, similarly, in
differences in the levels of CAF apoptosis in PaCa8 and PaCa13
tumours. This highlights the value of primary human tumour
models in the pre-clinical evaluation of experimental treatment
modalities (Rubio-Viqueira et al, 2006). In addition to anti-
angiogenesis, immunostimulation has also been shown to mediate
the anti-tumour effects of metronomic cyclophosphamide
(Hermans et al, 2003; Ghiringhelli et al, 2004, 2007; Loeffler
et al, 2005). The effect of metronomic gemcitabine on the immune
system, however, has not been reported in the literature, although
a recent study showed that conventional MTD gemcitabine
regimen (3 weeks on, 1 week off) reduces CD8
þ T cells, increases
CD11c
þ dendritic cells, but does not significantly alter the number
of CD4
þ T cells in pancreatic cancer patients after one cycle of
treatment when compared with pre-treatment baseline (Soeda
et al, 2009). The possibility that immunomodulation may have a
role in mediating the anti-tumour effects of metronomic
gemcitabine cannot be excluded.
In conclusion, our results showed that metronomic gemcitabine
is well tolerated and more effective than MTD gemcitabine in
pancreatic cancer. It markedly reduces tumour levels of various
pro-angiogenic molecules, and improves tumour vascular function
and tissue perfusion (as reflected by the increase in K
trans and the
decrease in tumour hypoxia). Pancreatic ductal adenocarcinoma is
characterised by a dense fibrovascular stroma consisting of
different cell types (e.g., cancer-associated fibroblasts, endothelial
cells, immune cells, and so on) (Bardeesy and DePinho, 2002).
These assorted populations of stromal cells and pancreatic cancer
cells are unlikely to all be in a susceptible growth phase at the time
when a single MTD of gemcitabine is administered once a week;
it follows that more frequent dosing at a lower but still effective
concentration of the drug would increase the probability of
eliminating or inducing differentiation in more cells of any cell
type (Kamen et al, 2006). Considering that suboptimal blood flow
(Komar et al, 2009) and hypoxia (Koong et al, 2000) contribute to
chemotherapy or radiotherapy failure in pancreatic cancer, it
would be interesting to evaluate whether the tumour physiological
changes (i.e., increased perfusion and decreased hypoxia) induced
by metronomic gemcitabine treatment as described in this study
may be exploited for the design of more effective combination
therapies. Oral formulations of an increasing number of che-
motherapeutic drugs are now available or are being developed. The
anti-tumour efficacy of oral gemcitabine (Veltkamp et al, 2008),
used in a metronomic regimen similar to the one described herein,
warrants clinical investigation in pancreatic cancer.
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